

DMB

1-13-00
FPA-00
J. M. Anderson

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee. This meeting was announced in the **Federal Register** of December 27, 1999 (64 FR 72355). The amendment is being made to cancel the entire session on January 27, 2000. This meeting will be open to the public. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Sandra L. Titus, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301-827-7001, or e-mail tituss@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area) code 12543. Please call the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of December 27, 1999 (64 FR 72355), FDA announced that a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee would be held on January 27 and 28, 2000. On page 72355, beginning in the first column, the *Date and Time*, *Agenda*, and *Procedure* portions of this meeting are amended to read as follows:

Date and Time: The meeting will be held January 28 from 8 a.m. to 5 p.m.

Location: Hilton, 620 Perry Ave., Gaithersburg, MD.


Agenda: On January 28, the committee will consider the safety and efficacy of new drug NDA 21-120, Novantrone® , (mitoxantrone, Immunex Corporation) proposed to treat secondary progressive multiple sclerosis, including progressive relapsing disease.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 20, 2000. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. on both days. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 20, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.


2).

Dated: January 7, 2000



Linda A. Suydam
Senior Associate Commissioner

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL



[FR Doc. 00-???? Filed ??-??-00; 8:45 am]

BILLING CODE 4160-01-F